Depletion of TREM2-expressing TAMs by mAbs was shown to have a robust anti-tumor response alone and in combination with anti-PD1 antibodies through enhanced CD8+ TILs infiltration and effector function in an orthotopic ovarian cancer mouse model [92]. Here, CD8A is linked to neoplasm.